Víctor Gil1, Alberto Domínguez-Rodríguez2, Josep Masip3,4,5, W Frank Peacock5,6, Òscar Miró7,4,5. 1. Emergency Department, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036, Barcelona, Catalonia, Spain. vgil@clinic.cat. 2. Cardiology Department, Hospital Universitario de Canarias, Tenerife, Spain. 3. Cardiology Department, Hospital Teknon, Barcelona, Catalonia, Spain. 4. University of Barcelona, Barcelona, Catalonia, Spain. 5. GREAT Network, Rome, Italy. 6. Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA. 7. Emergency Department, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036, Barcelona, Catalonia, Spain.
Abstract
PURPOSE OF REVIEW: To analyze whether the use of morphine, as initial treatment in acute cardiogenic pulmonary edema (ACPE), has an impact in clinical outcomes and mortality. A systematic review of the literature was performed, including all the studies comparing clinical outcomes in patients with ACPE who were treated or not with morphine. RECENT FINDINGS: Seven studies were selected, none of which were a randomized trial focused on answering the aim of this systematic review. The studies consisted of clinical trial secondary analysis assessing non-invasive ventilation in ACPE, one open non-randomized trial, two propensity score evaluations from large registries, and three clinical case reviews. Most of the studies showed unfavorable results with the use of morphine in terms of adverse events and mortality, and many of them were statistically significant. Finally, the ongoing MIdazolam versus MOrphine in acute cardiogenic pulmonary edema (MIMO) trial was specifically designed to compare the results of morphine use versus midazolam. The potential hemodynamic and sedative benefit of the use of morphine for vasodilatation and dyspnea amelioration may be opposed by an increase in mortality, ICU admission, and adverse events. Until there is a randomized clinical trial, the use of morphine for ACPE should be limited.
PURPOSE OF REVIEW: To analyze whether the use of morphine, as initial treatment in acute cardiogenic pulmonary edema (ACPE), has an impact in clinical outcomes and mortality. A systematic review of the literature was performed, including all the studies comparing clinical outcomes in patients with ACPE who were treated or not with morphine. RECENT FINDINGS: Seven studies were selected, none of which were a randomized trial focused on answering the aim of this systematic review. The studies consisted of clinical trial secondary analysis assessing non-invasive ventilation in ACPE, one open non-randomized trial, two propensity score evaluations from large registries, and three clinical case reviews. Most of the studies showed unfavorable results with the use of morphine in terms of adverse events and mortality, and many of them were statistically significant. Finally, the ongoing MIdazolam versus MOrphine in acute cardiogenic pulmonary edema (MIMO) trial was specifically designed to compare the results of morphine use versus midazolam. The potential hemodynamic and sedative benefit of the use of morphine for vasodilatation and dyspnea amelioration may be opposed by an increase in mortality, ICU admission, and adverse events. Until there is a randomized clinical trial, the use of morphine for ACPE should be limited.
Authors: José Manuel Carratalá; Salvador Díaz Lobato; Benjamin Brouzet; Patricio Más-Serrano; Begoña Espinosa; Pere Llorens Journal: Emergencias Date: 2018 Dic Impact factor: 3.881
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: Circulation Date: 2016-05-20 Impact factor: 29.690
Authors: Gysèle S Bleumink; Anneke M Knetsch; Miriam C J M Sturkenboom; Sabine M J M Straus; Albert Hofman; Jaap W Deckers; Jacqueline C M Witteman; Bruno H Ch Stricker Journal: Eur Heart J Date: 2004-09 Impact factor: 29.983
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Josep Masip; W Frank Peacok; Mattia Arrigo; Xavier Rossello; Elke Platz; Louise Cullen; Alexandre Mebazaa; Susanna Price; Héctor Bueno; Salvatore Di Somma; Mucio Tavares; Martin R Cowie; Alan Maisel; Christian Mueller; Òsar Miró Journal: Eur Heart J Acute Cardiovasc Care Date: 2022-02-08